EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen iD, Thorsten Oliver Götze, Peter Thuss-Patience iD, Matthias Biebl iD, Nils Homann, Michael Schenk, Udo Lindig, Vera Heuer, Albrecht Kretzschmar, Eray Goekkurt, Georg Martin Haag iD, Jorge Riera-Knorrenschild und 15 weitere

Journal of Clinical Oncology · 01.02.2024 · 42 (4) · 410-420

DOI: 10.1200/jco.23.00975 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2024. Verfasst von Sylvie Lorenzen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum rechts der Isar, Klinik für Innere Medizin III, Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 228-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a perioperative treatment for patients with resectable esophagogastric adenocarcinoma (EGA). METHODS DANTE started as multicenter, randomized phase II trial, which was subsequently converted to a phase III trial. Here, we present the results of the phase II proportion, focusing on surgical pathology and safety outcomes on an exploratory basis. Patients with resectable EGA (≥cT2 or cN+) were assigned to either four preoperative and postoperative cycles of FLOT combined with ATZ, followed by eight cycles of ATZ maintenance (arm A) or FLOT alone (arm B). RESULTS Two hundred ninety-five patients were randomly assigned (A, 146; B, 149) with balanced baseline characteristics between arms. Twenty-three patients (8%) had tumors with microsatellite instability (MSI), and 58% patients had tumors with a PD-L1 combined positive score (CPS) of ≥1. Surgical morbidity (A, 45%; B, 42%) and 60-day mortality (A, 3%; B, 2%) were comparable between arms. Downstaging favored arm A versus arm B (ypT0, 23% v 15% [one-sided P = .044]; ypT0-T2, 61% v 48% [one-sided P = .015]; ypN0, 68% v 54% [one-sided P = .012]). Histopathologic complete regression rates (pathologic complete response or TRG1a) were higher after FLOT plus ATZ (A, 24%; B, 15%; one-sided P = .032), and the difference was more pronounced in the PD-L1 CPS ≥10 (A, 33%; B, 12%) and MSI (A, 63%; B, 27%) subpopulations. Complete margin-free (R0) resection rates were relatively high in both arms (A, 96%; B, 95%). The incidence and severity of adverse events were similar in both groups. CONCLUSION Within the limitations of the exploratory nature of the data, the addition of ATZ to perioperative FLOT is safe and improved postoperative stage and histopathologic regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibodies, Monoclonal, HumanizedEsophageal NeoplasmsStomach NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenDocetaxelEsophagogastric JunctionFluorouracilLeucovorinNeoadjuvant TherapyOxaliplatin

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenDocetaxelFluorouracilLeucovorinOxaliplatin

Autor:innen und Institutionen

  • Klinikum rechts der Isar, Klinik für Innere Medizin III, Technische Universität München, Munich, Germany.
  • Frankfurter Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt, Germany.
  • Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt, Germany.
  • Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Chirurgische Klinik, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Klinikum Wolfsburg, MED. Klinik II, Wolfsburg, Germany.

ORCID-Profile: Sylvie Lorenzen, Peter Thuss-Patience, Matthias Biebl, Georg Martin Haag, Ralf-Dieter Hofheinz, Tianzuo Zhan, Thomas Jens Ettrich, Alexander Reinhard Siebenhuener, Moustafa Elshafei, Wolf Otto Bechstein, Timo Gaiser, Maria Loose, Christina Kopp

Zitieren

APA

Lorenzen, S., Götze, T. O., Thuss-Patience, P., Biebl, M., Homann, N., Schenk, M., Lindig, U., Heuer, V., Kretzschmar, A., Goekkurt, E., Haag, G. M., Riera-Knorrenschild, J., Bolling, C., Hofheinz, R. D., Zhan, T., Angermeier, S., Ettrich, T. J., Siebenhuener, A. R., Elshafei, M., …, & AIO and SAKK Study Working Groups (2024). Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. Journal of Clinical Oncology, 42(4), 410-420. https://doi.org/10.1200/jco.23.00975

Vancouver

Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. Journal of Clinical Oncology. 2024;42(4):410-420. doi:10.1200/jco.23.00975

BibTeX
@article{Lorenzen2024,
  author = {Lorenzen, Sylvie and Götze, Thorsten Oliver and Thuss-Patience, Peter and Biebl, Matthias and Homann, Nils and Schenk, Michael and Lindig, Udo and Heuer, Vera and Kretzschmar, Albrecht and Goekkurt, Eray and Haag, Georg Martin and Riera-Knorrenschild, Jorge and Bolling, Claus and Hofheinz, Ralf-Dieter and Zhan, Tianzuo and Angermeier, Stefan and Ettrich, Thomas Jens and Siebenhuener, Alexander Reinhard and Elshafei, Moustafa and Bechstein, Wolf Otto and Gaiser, Timo and Loose, Maria and Sookthai, Disorn and Kopp, Christina and Pauligk, Claudia and Al-Batran, Salah-Eddin and AIO and SAKK Study Working Groups, AIO and SAKK Study Working Groups},
  title = {Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {4},
  pages = {410--420},
  doi = {10.1200/jco.23.00975}
}
Kostenlos starten →